Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.35 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.31 |
| ▸ | ECE1 | P42892 | 1/20 | 0.31 |
| ▸ | KDM1A | O60341 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8083031 | 0.79 | MAPT (0.42) | MAPTHDAC2POLBPIK3CDSMN1; SMN2 | |
| SCHEMBL8277450 | 0.79 | MAPT (0.46) | MAPTHDAC2POLBPIK3CDSMN1; SMN2 | |
| SCHEMBL20349694 | 0.79 | MAPT (0.42) | MAPTHDAC2POLBPIK3CDSMN1; SMN2 | |
| SCHEMBL13385188 | 0.79 | MAPT (0.46) | MAPTHDAC2POLBPIK3CDSMN1; SMN2 | |
| SCHEMBL24568173 | 0.77 | MAPT (0.43) | MAPTHDAC2POLBPIK3CDSMN1; SMN2 | |
| SCHEMBL16139219 | 0.77 | MAPT (0.43) | MAPTHDAC2POLBPIK3CDSMN1; SMN2 | |
| SCHEMBL8013070 | 0.76 | MAPT (0.46) | MAPTHDAC2POLBPIK3CDSMN1; SMN2 | |
| SCHEMBL18272884 | 0.76 | HDAC2 (0.42) | MAPTHDAC2POLBSMN1; SMN2ALDH1A1 | |
| SCHEMBL21734331 | 0.76 | MAPT (0.44) | MAPTHDAC2POLBPIK3CDSMN1; SMN2 | |
| SCHEMBL14038364 | 0.76 | HDAC2 (0.42) | MAPTHDAC2POLBSMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080292587-A1 | OXIMYL DIPEPTIDE HEPATITIS C PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2008-11-27 | — | — | US | disclosed |
| US-20080292587-A1 | OXIMYL DIPEPTIDE HEPATITIS C PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2008-11-27 | — | — | US | disclosed |
| WO-2008134398-A1 | OXIMYL DIPEPTIDE HEPATITIS C PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2008-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080292587-A1 | OXIMYL DIPEPTIDE HEPATITIS C PROTEASE INHIBITORS | DPP4, PREP, PEPD | MAPT 4377/4885HDAC2 2383/4885POLB 2455/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.